Clinical trial
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human…
NCT00481767 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00481767 |
|---|---|
| Title | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. |
| Official title | Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Human Papillomavirus (HPV) Infection |
| Intervention type | Biological, Drug |
| Interventions | Cervarix, Placebo Al(OH)3 |
| Enrollment | 676 |
| Start date | Oct 1, 2007 |
| Primary completion | Feb 25, 2010 |
| Completion | Jul 26, 2010 |
| First posted | Jun 4, 2007 |
| Last update posted | Nov 17, 2020 |
| Countries | Senegal, Tanzania |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: